BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Down 6.3%

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report)'s share price traded down 6.3% during trading on Friday . The company traded as low as $4.77 and last traded at $4.78. 1,389,096 shares were traded during mid-day trading, a decline of 57% from the average session volume of 3,262,208 shares. The stock had previously closed at $5.10.

Analyst Ratings Changes

Separately, Needham & Company LLC reissued a "buy" rating and issued a $12.00 target price on shares of BioCryst Pharmaceuticals in a report on Wednesday. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $13.29.

BioCryst Pharmaceuticals Trading Down 6.5 %

The firm has a market cap of $983.34 million, a price-to-earnings ratio of -4.04 and a beta of 1.90. The firm has a 50 day moving average price of $5.29 and a 200-day moving average price of $5.69.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last released its quarterly earnings results on Monday, February 26th. The biotechnology company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.04). The business had revenue of $93.40 million during the quarter, compared to the consensus estimate of $89.19 million. As a group, equities analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.62 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the stock. Fifth Third Bancorp increased its stake in BioCryst Pharmaceuticals by 17,500.0% in the third quarter. Fifth Third Bancorp now owns 3,520 shares of the biotechnology company's stock valued at $25,000 after purchasing an additional 3,500 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its stake in BioCryst Pharmaceuticals by 96.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 4,865 shares of the biotechnology company's stock valued at $34,000 after purchasing an additional 2,388 shares during the last quarter. Fairfield Bush & CO. acquired a new position in BioCryst Pharmaceuticals in the first quarter valued at $34,000. State of Wyoming acquired a new position in BioCryst Pharmaceuticals in the fourth quarter valued at $35,000. Finally, Advisory Services Network LLC increased its stake in BioCryst Pharmaceuticals by 46.3% in the first quarter. Advisory Services Network LLC now owns 4,740 shares of the biotechnology company's stock valued at $40,000 after purchasing an additional 1,500 shares during the last quarter. 85.88% of the stock is owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.